Cyclovirobuxine D (CVB-D) 是中药黄杨Buxus microphylla的主要活性成分。Cyclovirobuxine D 诱导自噬并减弱Akt和mTOR的磷酸化。Cyclovirobuxine D 通过抑制细胞周期进程和诱导线粒体介导的细胞凋亡apoptosis抑制癌细胞的增殖。Cyclovirobuxine D 有潜力用于心肌梗死引起的心力衰竭的研究。
生物活性 | Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicineBuxus microphylla. Cyclovirobuxine D inducesautophagyand attenuates the phosphorylation ofAktandmTOR[1]. Cyclovirobuxine D inhibits cell proliferation of gastriccancercells through suppression of cell cycle progression and inducement of mitochondria-mediatedapoptosis[2]. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction[3]. |
体外研究 (In Vitro) | Cyclovirobuxine D (0-240 μM ;24-72 hours) shows a concentration- and time-dependent reduced cell viability after CVB-D treatment, only 10% MGC-803 cells and 20% MKN28 cells are alive at 72 h after treatment with 240 μM[2].Cyclovirobuxine D (0-120 μM; 48 hours) arrests the cell cycle of gastric cancer cells at S phase in a concentration-dependent manner[2].Cyclovirobuxine D (0-120 μM; 48 hours) leads to apoptosis in gastric cancer cells in a concentration-dependent manner, especially early stage apoptosis.
Cyclovirobuxine D (0-120 μM; 48 hours) causes apoptosis via up-regulation of the apoptosis- related proteins, cleaved Caspase-3 and ratio of Bax/Bcl-2, in gastric cancer cells[2].
Cell Viability Assay[2] Cell Line: | MGC-803 and MKN28 cells | Concentration: | 0, 30, 60, 120 and 240 μM | Incubation Time: | 24, 48, 72 hours | Result: | Reduced Cell Viability and Colony Formation Ability of Gastric Cancer Cells |
Cell Cycle Analysis[2] Cell Line: | MGC-803 and MKN28 cells | Concentration: | 0, 30, 60, and 120 μM | Incubation Time: | 48 hours | Result: | Arrested cell cycle progressions of MGC-803 and MKN28 cells. |
Apoptosis Analysis[2] Cell Line: | MGC-803 and MKN28 cells | Concentration: | 0, 30, 60, and 120 μM | Incubation Time: | 48 hours | Result: | Induced apoptosis of MGC-803 and MKN28 cells. |
Western Blot Analysis[2] Cell Line: | MGC-803 and MKN28 cells | Concentration: | 0, 30, 60, and 120 μM | Incubation Time: | 48 hours | Result: | Up-regulated cleaved Caspase-3 and Bax and decreased the expression of Bcl-2 expression. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | - Plants
- Buxaceae
- Buxus microphyllaS.et Z.var. Sinica Rehd.et Wils.
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: Ethanol : 13 mg/mL(32.29 mM;Need ultrasonic) 配制储备液 1 mM | 2.4835 mL | 12.4174 mL | 24.8348 mL | 5 mM | 0.4967 mL | 2.4835 mL | 4.9670 mL | 10 mM | 0.2483 mL | 1.2417 mL | 2.4835 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% EtOH 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 1.08 mg/mL (2.68 mM); Clear solution
此方案可获得 ≥ 1.08 mg/mL (2.68 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 10.8 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% EtOH 90% (20%SBE-β-CDin saline) Solubility: ≥ 1.08 mg/mL (2.68 mM); Clear solution
此方案可获得 ≥ 1.08 mg/mL (2.68 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 10.8 mg/mL 的澄清 EtOH 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% EtOH 90%corn oil Solubility: ≥ 1.08 mg/mL (2.68 mM); Clear solution
此方案可获得 ≥ 1.08 mg/mL (2.68 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 10.8 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|